Credentis ag Announces Successful Closing of B-Round Financing

Published: Mar 11, 2013

March 11, 2013 -- Credentis ag announces a first closing of its B-round financing. Investments currently amounting to a minimum of 1.59 Mio CHF were made solely by management and existing investors including cantonal banks ZKB and AKB, StartAngels Network, BioBAC Angels, and a number of private investors including known dentists and exponents of the dental industry. “The new capital will allow us to start launching Curodont™ Repair and complete the development of Curodont™ Protect, the second product with the Curolox™ Technology”, says credentis CEO Dr Dominik Lysek.

About Curodont™ product line

Curolox™ Technologyis based on peptides self-assembling into a matrix triggering the body’s own tooth regeneration and repair mechanism. Curolox™ is the basis for all of credentis’ products incl. Curodont™ Repair, for which credentis has obtained market approval (CE-label). Curodont™ Repair provides dentists with a novel technology to regenerate rather than repair carious and similar tooth lesions. Applied to an early lesion, Curodont™-Repair forms a scaffold of small fibres within the lesion around which new enamel or dentin can form and grow. Ideally, within several weeks the lesion will regenerate without the use of burr or filler. This effect is observed in a growing number of patients both in clinical studies and daily practice settings. Curodont™ Protect uses the same technology to protect the tooth surface or treat unpleasant sensations such as dentin hypersensitivity by laying a network of fibers over the tooth surface. “The additional capital enables us to start launching Curodont™ Repair in various markets and to complete development of Curodont™ Protect. Working with dental professionals, credentis seeks to support with its product line a novel approach to caries treatment and prevention. Curodont™ Repair has its potential in the treatment of dental caries, whereas Curodont™ Protect has its main benefit in preventing tooth decay and in the treatment of dentin hypersensitivity!” explains CEO Dominik Lysek. The ultimate goal is to prevent caries by the use of its regenerative product line and frequent dental recalls by dentists and dental hygienists.

About credentis ag

credentis is currently headquartered in the Technopark Aargau Switzerland, Windisch (credentis has won multiple startup awards including Swiss Venture Leader 2011 as well as support from startup organizations like Genilem and multiple public grants incl. Swiss National Fonds, Aargauer Forschungsfond and the Medical Technologies IKC together with the University of Leeds. CEO Dominik Lysek and CTO Michael Hug have expert knowledge in medicinal technology and a strong network in the dental industry. credentis board members Dr. Werner Berner and Dr. Erich Platzer (chairman), both members of the StartAngels Network, contribute their expert knowledge of industry and finance.

Back to news